This Article Full Text Full Text (PDF) Erratum (v22,p2973) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kumar, S. Articles by Rajkumar, S. V. Search for Related Content PubMed PubMed Citation Articles by Kumar, S. Articles by Rajkumar, S. V. Social Bookmarking                            What's this?

Thalidomide: Current Role in the Treatment of Non-Plasma Cell Malignancies

From the Division of Hematology, Department of Internal Medicine, Mayo Clinic and Foundation, Rochester, MN

Address reprint requests to S. Vincent Rajkumar, MD, Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905; e-mail: rajks{at}mayo.edu

Thalidomide, initially introduced as a sedative, was withdrawn from the market in the early 1960s after it was found to be a teratogen. However, it later found use as an investigational agent in the treatment of erythema nodosum leprosum, oral ulcers, graft versus host disease, and wasting associated with the human immunodeficiency syndrome. Its antiangiogenic properties were recognized in the early 1990s during a period where the importance of angiogenesis became increasingly apparent as a critical step in the in the proliferation and spread of malignant neoplasms. This led to the evaluation of thalidomide as an antiangiogenic agent in the treatment of several cancers. Thalidomide has already become part of standard therapy for the treatment of patients with relapsed and refractory multiple myeloma. It has also been found to have varying degree of benefit in various other malignancies. Although more clinical trials are needed, Kaposi's sarcoma and myelofibrosis represent other malignancies in which thalidomide has already demonstrated promising activity. The mechanism of action of thalidomide in cancer is still unclear, but do appear to be mediated by several other mechanisms in addition to its anti-angiogenic properties. This article reviews the current status of thalidomide for the treatment of non-plasma-cell malignancies.

Supported in part by grants CA85818, CA93842, CA100080, and CA62242 from the National Cancer Institute, Bethesda, MD. Also supported in part by the Multiple Myeloma Research Foundation, the Goldman Philanthropic Partnerships, and the Leukemia and Lymphoma Society.

The authors have received research support for clinical trials using thalidomide from Celgene.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				B. Vahid and P. E. Marik Pulmonary Complications of Novel Antineoplastic Agents for Solid Tumors Chest, February 1, 2008; 133(2): 528 - 538. [Abstract] [Full Text] [PDF]

				I. Dimopoulou, A. Bamias, P. Lyberopoulos, and M. A. Dimopoulos Pulmonary toxicity from novel antineoplastic agents Ann. Onc., March 1, 2006; 17(3): 372 - 379. [Abstract] [Full Text] [PDF]

				S. V. Rajkumar, E. Blood, D. Vesole, R. Fonseca, and P. R. Greipp Phase III Clinical Trial of Thalidomide Plus Dexamethasone Compared With Dexamethasone Alone in Newly Diagnosed Multiple Myeloma: A Clinical Trial Coordinated by the Eastern Cooperative Oncology Group J. Clin. Oncol., January 20, 2006; 24(3): 431 - 436. [Abstract] [Full Text] [PDF]

				S. V. Rajkumar Thalidomide Therapy and Deep Venous Thrombosis in Multiple Myeloma Mayo Clin. Proc., December 1, 2005; 80(12): 1549 - 1551. [PDF]

				S. V. Rajkumar and R. A. Kyle Multiple Myeloma: Diagnosis and Treatment Mayo Clin. Proc., October 1, 2005; 80(10): 1371 - 1382. [Abstract] [PDF]

				A. Vacca, C. Scavelli, V. Montefusco, G. Di Pietro, A. Neri, M. Mattioli, S. Bicciato, B. Nico, D. Ribatti, F. Dammacco, et al. Thalidomide Downregulates Angiogenic Genes in Bone Marrow Endothelial Cells of Patients With Active Multiple Myeloma J. Clin. Oncol., August 10, 2005; 23(23): 5334 - 5346. [Abstract] [Full Text] [PDF]

				T. Yabu, H. Tomimoto, Y. Taguchi, S. Yamaoka, Y. Igarashi, and T. Okazaki Thalidomide-induced antiangiogenic action is mediated by ceramide through depletion of VEGF receptors, and is antagonized by sphingosine-1-phosphate Blood, July 1, 2005; 106(1): 125 - 134. [Abstract] [Full Text] [PDF]